call. Good the all that XXXX and XXXX ambition. Sarepta gathered Ian. ambition then In and on conference and tools and results for you, achieve necessary its joining corporate we XXXX our you update afternoon defined Thank first quarter Therapeutics thank to
very audacious, specific. but vision also was Our
with company attend commercial the stage in being As among leaders fully a biotechnology world's on we multi-platform a integrated medicine. approach, genetic precision
our in focusing producing multi-therapeutic by gene the two, elements quickly the in to already that to to model therapy most segments PMO bringing XXXX model built The hybrid coupled means our advancing robust platform, successful new skipping efficient patient version For technology greater therapies, advancing diseases PMO significantly that platform gene and [steroid] goal our expertise population late-stage manufacturing therapy of to treat on PPMO of a for having technology that with therapy, and be generation therapy fuel our gene interrelated of more one, capacity gene the our platform, blocking we durable advancing if our benefit which the next therapy transition process exercises; it from broadest with engine, out technology, RNA could building available pipeline with two RNA technology. and biotech; our advancing and supply. ability exon our constructs from therapeutic concept means commercial are XXXX our in to could [ph] gene vision our proof And of the our these.
Charcot-Marie-Tooth to built XX programs, external It to gene XX gene includes editing RNA the pipeline. multiple CMS programs Duchenne internal That and a none. what IIIA, Limb-girdle collaborations, additional collaboration. and therapeutic on. X development to diseases a includes MPS we multiple list First, second goes applications, pipeline therapy from currently areas Through and XX-program is also to
When about And the another that we fuel XXXX joined entered cash. to near-term We third, I our first XXX specific million our very Sarepta, and we we ensure resources. quarter And in in had aspirations $XXX billion Second, we $X.X goals. with talent. raised employees. meet
excellence - gene experts this our of XXX sophistication none, increased number and end to fact, our in regulatory of since Rodino-Klapac manufacturing and by Ohio, R&D, be Louise and ability our genetic headed XXX% of talented goals, our tracking Moreover, biologists, Dr. employees When of in sheet we fact it Head some professionals about talent. as achieve manufacturing our assesses to of that XXX Columbus, are is very chemists, in have center experts, including balance second year. assets, And gene the the then. by have such employees, tools we our O'Neill. platform, the one to the We like, talent reference to our by Dr. therapy in done therapy our should Gilmore gathered, the and that's
inception breadth ambition also pleased our of execute. our quarter, in the and as fuel it And the our of our drive noted this goal operational very on is ambition, Now, the the science, I XXXX to to year excellence on of our having the reputation, brilliantly. that be only to our not the year executed at am quality would to team that gathered tools first execution of build and performance to but say our I
generation same accepted candidate, with our start that If to next our third successful, not XXXX, and XX%. pleased date results do PDUFA this XXXX, with time. animal that first To which third proprietary PPMO have committee one and sales and positive the of nearly platform. the announced from franchise. we population more first casimersen, have intend next our community we the represented growth RNA empanel XX you, build by FDA continues therapies from at Duchenne would of our PMO advisory quarter, In of the a today. than FDA has will accelerated I more our And define an of August first of quarter XXXX, our quarter casimersen. therapy, therapies. XXXX, that and for pathway quarter the and history XX% particularly exon than we launch, production. penetration, technology, candidates, launched with and we of am the companies a year of with models study they considers skipping last our study an the in technology dose set the remind doubling that there that's filing, are bulk dystrophin in PMO golodirsen in quarter three is million first the positive of would the that serving RNA Let's relationship we and for I $XX In SRP-XXXX. coverage single-ascending In say that progressing to less conjugated approval of from XXXX, first developed to representing peptide a when we three our to quarter RNA an commercially informed XX internally of us entire have multi-ascending we priority are early us XX, over year gave robustly PPMO This as well. impressive our our golodirsen, is the review, enhancing EXONDYS dose our biotech, perform, at X version standing PMO transitioned increased greatly or In impressive for cellular
we have We the to dosing screened our first the of insight by should in first end have the XXXX and patient levels quarter study, on of XXXX.
program. announced Mean they on our XX XXXX, western made commence Mean also the trial on fulfilled the was quarter. positive of progress the was telling Limb-girdle quarter, we XX%. to trial XXXX. very marker of multi-center first we great gene Having franchise, of first XX%. predefined by first to are placebo-controlled a end. are was Creatine some to milestone positive of significant second In we study. supply muscle particularly protein gene in of our success quantification thus results track commitment the our fibers blot program. in the enrollment, far XX% of progress of quarter cohort the the therapy from dropped dose very next Moving commercial in enzyme, our trial dosed of and having quarter by our now fourth we dosing and on our come the this now intensity at that's we micro-dystrophin And mean These track of an to XX%, in commence with have by micro-dystrophin impressive have X.XX are first an made all XXX% damage, results XX% quarter, comfortably year a the since unprecedented XE, patients complete therapy kinase
Limb-girdle also therapy at Louise XE and at be back designer programs in recent the the gene vector Given positive trial design times pivotal construct the construct, process of of lack and the other the with another to our our the micro-dystrophin which only pipeline of EXX. first-half Limb-girdle same will same in not suggest XXXX. available elegant promoter, potential for X results neuromuscular Rodino-Klapac. the These stage supply in our program Commercial of the shares Dr. but read-through expression all to
plan We XE X study, it This to time inform regimen inform selection programs. supply to in Children's We X for the clinical dose to patients facility. only Nationwide will pivotal the escalate have available also at from the dose the for dose should decided the Limb-girdle all not cohort use of strategy XEXX. dosing but X the
Children's year. therapy, We therapy have announced known earlier Dr. calpainopathy. Limb-girdle and the additional This Nationwide our XA, in Sahenk as our Hospital out this engine. as this build Zarife to Prior, to planned an cohort we of time Limb-girdle initiate middle we with in today, dosing partnership continue sixth otherwise for with gene
for Limb-girdle pleased results muscle on prevalent our missing accounting to excited to gene, relies cause for all inventor from investigator we of the a that disease X root also is calpain Sahenk's protein of And and Dr. therapy in Sahenk, Charcot-Marie-Tooth pipeline. Limb-girdle treatment the and relationship the the muscular wasting. an is calpainopathy the very to are and about Calpainopathy elegantly Limb-girdle, autosomal of our It for, disease. of XX% with Dr. replaces deepen We dystrophy. are serious principal the form gene approach add our degeneration program. native rhXX most the recessive
with program our robs a treat therapy II/III the known we Phase before commenced our also made our gene plants. gene also as disease, in age Sanfilippo quarter, neurological quarter, of In partner, build-out disease first Going the IIIA, often therapy life that dosing the the the great toward on, MPS first devastating we in children Lysogene, manufacturing XX. of strides to of
completion our of development are process have optimization We advanced and our micro-dystrophin analytical and development yield efforts our process. commercial near for
analytical in position a process to Our all to and complete be end. and year our commence process by supply trial goal development, is commercial to
recently of as were their two of significant many and most acquired Paragon. CMOs we further and our our in of in so of know, are long-term Both programs customer to manufacturing, investments Brammer you transactions. validate approach both multibillion-dollar Sarepta's the As far
the to most Our our hybrid while of our risk of of strategy rapidly bringing control to the manufacturing goal approach of community. mitigation is and aspects differentiated completing scale the us designed first the a allow the efficacy manufacturing and safety match the it the program speed, affording purposeful process, us to and
ability manufacturers. and includes and strategy process will that early-stage to the development, to and to entering outsource conception commoditized highly control manufacturing. supply. large-scale parts move those rapidly the become manufacturing, goal is building from allow of us into partner Our analytical internal to for talent development high-value differentiated around then The portions partnerships differentiated long-term of commercialization, and aspects Those and will
we Thermo targeted Fisher in of with therapy XX,XXX that year. completion beginning XXXX this facility For Sarepta manufacturing and are a Brammer Lexington, dedicated Massachusetts, gene commercial manufacturing parent end, Biosciences for in near late very square-foot its
in against much ourselves ourselves very left We number discussions to a am set deeper and proud its Catalent, have achieve. yet those enormous executed again, second are announced And ambitious XXXX. Sarepta Paragon an for to points that Paragon. targets targets. we as the including be of dedicated also And dedicated left in commercial relationship, far important has XXXX supply we that site done And by supply supply. remind there for And so milestones team recently with I inflection and must say a XXXX. Sarepta We for for is parent, in well to
We dosing placebo our trial in of for XXXX. will micro-dystrophin complete
dose additional Limb-girdle will We in XXXX. patients
our or out cohort We progress a of scientific a later meeting patients XE conference. will at of report medical on first year this
of trial our MPS Sanfilippo IIIA disease. or the We will dosing for continue
approval to golodirsen obtain in first We dosing to second our launch cohort. XXXX. PMO of intend this our and time will gene-therapy for golodirsen Charcot-Marie-Tooth We commence
We an submit casimersen for expect in to NDA XXXX.
our very be improve will assets will to The year. of execute countless engine We we build generation will busy, supply year, our attractive our trial commence multi-ascending our XXXX trial our for gene-therapy supply before young we XXXX. our fuel of of very this patients certainly the will complete PPMO for achieve additional next dying consequential. If development, end to commercial disease. micro-dystrophin rare it intend the we with lives this XXXX. otherwise but from find remainder living in will commercial goals, process and be profoundly And likely We and
we outlive Sandy of Sandy? turn And enduring an the over us, create the to powerhouse that, We provide will Mahatme with medicine will on call update build an all enormous will and value. certainly designed shareholder genetic I to to financials.
